By Associated Press

U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

The Food and Drug Administration said Friday it approved the pill Sovaldi in combination with older drugs to treat the main forms of hepatitis C that affect U.S. patients.